You've just added:

Our Impact

How we're advancing cures globally

177

Medicines in the making

64

Institutions supported

36

Companies launched

19

Medicines in the clinic

15

Licenses to pharma

What sets us apart

In addition to receiving funding, every scholar is paired with a results-oriented and mission-focused team from our Therapeutics Development Center. Teams consist of a project manager and experienced pharma and business development advisors with a track record of bringing new drugs to market.

Learn More

Making discoveries partner-ready

Our pipeline represents the best science coming out of academic laboratories. Projects are selected for their innovation and potential for clinical impact. Our team proactively moves them forward to commercial viability and clinical use.

See all discoveries

Accelerating Scientific Breakthroughs

Our pipeline represents the best science coming out of academic laboratories. Projects are selected for their innovation and potential for clinical impact. Our team proactively moves them forward to commercial viability and clinical use.

See all discoveries

The Latest

See All News
2021-2022 Harrington Annual Publication

Annual Publications

2021-2022 Harrington Annual Publication

First Ten Years. Accelerating Discoveries into Medicines.

Continue Reading
The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

Press Releases

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

The Therapeutics Accelerator will identify, fund and advance innovative projects from academic partners in the U.K. and U.S. with the goal to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over 10 years.

Continue Reading
AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

Press Releases

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC)

Continue Reading

Sign Up

Become a part of our community and receive periodic communications with news and updates, as well as notifications of grant funding opportunities.